• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Impact of high human genetic diversity in Africa on immunogenicity and efficacy of RTS,S/AS01 vaccine.非洲人类遗传高度多样性对 RTS,S/AS01 疫苗免疫原性和效果的影响。
Immunogenetics. 2023 Jun;75(3):207-214. doi: 10.1007/s00251-023-01306-8. Epub 2023 Apr 21.
2
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.RTS,S/AS01E 候选疟疾疫苗与扩大免疫规划疫苗联合接种的安全性和有效性：一项随机、开放标签、2 期临床试验的 19 个月随访。
Lancet Infect Dis. 2011 Oct;11(10):741-9. doi: 10.1016/S1473-3099(11)70100-1. Epub 2011 Jul 22.
3
Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.RTS,S/AS01疟疾疫苗在世界卫生组织1期或2期HIV疾病婴幼儿中的安全性和免疫原性：一项随机、双盲、对照试验。
Lancet Infect Dis. 2016 Oct;16(10):1134-1144. doi: 10.1016/S1473-3099(16)30161-X. Epub 2016 Jul 7.
4
Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.在非洲不同传播环境下评估 RTS,S/AS01 疟疾疫苗在儿童中的疗效的 III 期多中心试验设计。
Malar J. 2011 Aug 4;10:224. doi: 10.1186/1475-2875-10-224.
5
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.在撒哈拉以南非洲的一项随机试验中，鉴定出 RTS,S/AS01 疟疾疫苗在婴儿和儿童中的安全性和免疫原性，这些婴儿和儿童被确定为 HIV 感染。
Vaccine. 2020 Jan 22;38(4):897-906. doi: 10.1016/j.vaccine.2019.10.077. Epub 2019 Nov 7.
6
Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.在非洲儿童中，RTS,S/AS01 疟疾疫苗对乙肝抗原的免疫应答，以及与肺炎球菌结合疫苗和轮状病毒疫苗联合使用：一项随机对照试验。
Hum Vaccin Immunother. 2018 Jun 3;14(6):1489-1500. doi: 10.1080/21645515.2018.1442996. Epub 2018 Apr 13.
7
Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.马拉维利隆圭 RTS,S/AS01 疟疾疫苗效力的环境修饰物。
BMC Public Health. 2020 Jun 12;20(1):910. doi: 10.1186/s12889-020-09039-z.
8
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.RTS,S/AS01 疟疾疫苗在婴幼儿中的安全性特征：撒哈拉以南非洲地区 III 期随机对照试验的补充数据。
Hum Vaccin Immunother. 2019;15(10):2386-2398. doi: 10.1080/21645515.2019.1586040. Epub 2019 Apr 23.
9
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.RTS,S/AS01 疟疾疫苗在非洲婴儿中的 3 期临床试验。
N Engl J Med. 2012 Dec 13;367(24):2284-95. doi: 10.1056/NEJMoa1208394. Epub 2012 Nov 9.
10
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.RTS,S/AS01E 疟疾疫苗候选者在 5 至 17 个月大的肯尼亚和坦桑尼亚儿童中的安全性。
PLoS One. 2010 Nov 29;5(11):e14090. doi: 10.1371/journal.pone.0014090.

引用本文的文献

1
Search continues: Exploring immunoinformatics platforms for designing an effective multiepitope malaria vaccine candidate.搜索仍在继续：探索用于设计有效多表位疟疾疫苗候选物的免疫信息学平台。
BioTechnologia (Pozn). 2025 Jun 30;106(2):151-168. doi: 10.5114/bta/204528. eCollection 2025.
2
Clinical and Laboratory Predictors of Poor Outcomes in Pediatric Cerebral Malaria in Nigeria.尼日利亚儿童脑型疟疾预后不良的临床和实验室预测因素
Oman Med J. 2024 Nov 30;39(6):e692. doi: 10.5001/omj.2024.112. eCollection 2024 Nov.
3
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.在乌干达接种辉瑞-生物科技公司BNT162b2疫苗的受种者中，加强接种后针对刺突蛋白的继发性IgG抗体反应减弱，这对当地的疫苗接种政策具有影响。
Front Immunol. 2024 Feb 16;15:1325387. doi: 10.3389/fimmu.2024.1325387. eCollection 2024.
4
Immunogenetics special issue 2023: Immunogenetics of infectious disease.《免疫遗传学》2023年特刊：传染病的免疫遗传学
Immunogenetics. 2023 Jun;75(3):197-199. doi: 10.1007/s00251-023-01301-z.

本文引用的文献

1
Reflections on the 2021 World Malaria Report and the future of malaria control.对 2021 年世界疟疾报告的思考及疟疾控制的未来
Malar J. 2022 May 27;21(1):154. doi: 10.1186/s12936-022-04178-7.
2
Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso.评估季节性疟疾化学预防对布基纳法索 5 岁以下儿童疟疾负担的影响。
Malar J. 2022 May 6;21(1):143. doi: 10.1186/s12936-022-04172-z.
3
WHO recommends malaria vaccine for children.世界卫生组织建议为儿童接种疟疾疫苗。
Lancet Infect Dis. 2021 Dec;21(12):1634. doi: 10.1016/S1473-3099(21)00711-8.
4
Ethical considerations for introducing RTS,S/AS01 in countries with moderate to high Plasmodium falciparum malaria transmission.在恶性疟原虫疟疾传播程度为中度至高度的国家引入RTS,S/AS01的伦理考量。
Lancet Glob Health. 2021 Dec;9(12):e1642-e1643. doi: 10.1016/S2214-109X(21)00498-8.
5
Recent Advances in Understanding the Inflammatory Response in Malaria: A Review of the Dual Role of Cytokines.疟疾中炎症反应的研究进展：细胞因子的双重作用综述
J Immunol Res. 2021 Nov 8;2021:7785180. doi: 10.1155/2021/7785180. eCollection 2021.
6
World Malaria Day 2021: Commemorating 15 Years of Contribution by the United States President's Malaria Initiative.2021 年世界疟疾日：纪念美国总统疟疾行动计划做出贡献 15 周年。
Am J Trop Med Hyg. 2021 Apr 23;104(6):1955-1959. doi: 10.4269/ajtmh.21-0432.
7
Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough?迈向消除疟疾：世界卫生组织的RTS,S/AS01疫苗是否足够有效？
Risk Manag Healthc Policy. 2021 Mar 12;14:1033-1039. doi: 10.2147/RMHP.S219294. eCollection 2021.
8
Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.撒哈拉以南非洲地区 RTS,S/AS01 疟疾疫苗分配策略的预估影响：建模研究。
PLoS Med. 2020 Nov 30;17(11):e1003377. doi: 10.1371/journal.pmed.1003377. eCollection 2020 Nov.
9
Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda.乌干达各地潜在的氨基喹啉、抗叶酸和青蒿素耐药性中介体的流行率变化。
J Infect Dis. 2021 Mar 29;223(6):985-994. doi: 10.1093/infdis/jiaa687.
10
Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.在马拉维利隆圭，使用 RTS,S/AS01 疟疾疫苗联合蚊帐来减少病例和控制成本效益。
Vaccine. 2020 May 22;38(25):4079-4087. doi: 10.1016/j.vaccine.2020.04.031. Epub 2020 Apr 30.

非洲人类遗传高度多样性对 RTS,S/AS01 疫苗免疫原性和效果的影响。

Impact of high human genetic diversity in Africa on immunogenicity and efficacy of RTS,S/AS01 vaccine.

机构信息

Infectious Diseases Research Collaboration, Kampala, Uganda.

Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

出版信息

Immunogenetics. 2023 Jun;75(3):207-214. doi: 10.1007/s00251-023-01306-8. Epub 2023 Apr 21.

DOI:10.1007/s00251-023-01306-8
PMID:37084013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10119520/
Abstract

In modern medicine, vaccination is one of the most effective public health strategies to prevent infectious diseases. Indisputably, vaccines have saved millions of lives by reducing the burden of many serious infections such as polio, tuberculosis, measles, pneumonia, and tetanus. Despite the recent recommendation by the World Health Organization (WHO) to roll out RTS,S/AS01, this malaria vaccine still faces major challenges of variability in its efficacy partly due to high genetic variation in humans and malaria parasites. Immune responses to malaria vary between individuals and populations. Human genetic variation in immune system genes is the probable cause for this heterogeneity. In this review, we will focus on human genetic factors that determine variable responses to vaccination and how variation in immune system genes affect the immunogenicity and efficacy of the RTS,S/AS01 vaccine.

摘要

在现代医学中，疫苗接种是预防传染病的最有效公共卫生策略之一。不可否认，疫苗通过减轻许多严重感染（如脊髓灰质炎、结核病、麻疹、肺炎和破伤风）的负担，挽救了数百万人的生命。尽管世界卫生组织（WHO）最近建议推出 RTS,S/AS01，但这种疟疾疫苗仍然面临着功效变化的主要挑战，部分原因是人类和疟疾寄生虫的遗传高度变异。疟疾的免疫反应在个体和人群之间存在差异。免疫系统基因的人类遗传变异可能是这种异质性的原因。在这篇综述中，我们将重点关注决定疫苗接种反应变化的人类遗传因素，以及免疫系统基因的变异如何影响 RTS,S/AS01 疫苗的免疫原性和功效。